Compare GOODO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Current Price
Current Price
| Metric | GOODO | LYEL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 320.1M |
| IPO Year | 2003 | 2021 |
| Metric | GOODO | LYEL |
|---|---|---|
| Price | $18.75 | $9.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $37.88 |
| AVG Volume (30 Days) | 5.4K | ★ 105.0K |
| Earning Date | N/A | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $161,336,000.00 | $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $106.22 | ★ N/A |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $19.01 | $9.45 |
| 52 Week High | $22.20 | $45.00 |
| Indicator | GOODO | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 25.52 | 27.89 |
| Support Level | N/A | N/A |
| Resistance Level | $20.32 | $15.38 |
| Average True Range (ATR) | 0.30 | 0.52 |
| MACD | -0.15 | -0.09 |
| Stochastic Oscillator | 10.77 | 12.67 |
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.